Ribomic rebounded for the first time in 14 days and raised its full-year operating earnings forecast. The revision was reportedly supported by lower-than-expected research and development expenses.
Ribomic's share price reportedly rebounded for the first time in 14 days. Information also emerged that the company's full-year operating earnings forecast had been revised upward.
The upward revision was reportedly attributable in part to research and development expenses coming in below expectations. This appears to have contributed to an improvement in the earnings outlook.
This information was reported as DZH Individual Stock Information by Jiji Press and published as a related article on Yahoo! Finance.
facts": []
sources": []
sources": []
facts": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
sources": []
notes": null
title":
note_ja": null
standfirst_ja":
notes": null
sources": []
facts": []
summary_paragraphs": []
sources": []
standfirst_ja":
sources": []
summary_paragraphs": []
sources": []
standfirst_ja":
summary_paragraphs": []
sources": []
standfirst_ja":
summary_paragraphs": []
sources": []
facts": []
standfirst_ja":
summary_paragraphs": []
sources": []
facts": []
summary_paragraphs": []
sources": []
standfirst_ja":
summary_paragraphs": []
sources": []
facts": []
summary_paragraphs": []
sources": []
standfirst_ja":
summary_paragraphs": []
sources": []
facts": []
summary_paragraphs": []
sources": []
standfirst_ja":
summary_paragraphs": []
sources": []
facts": []
summary_paragraphs": []
sources": []
standfirst_ja":
summary_paragraphs": []
sources": []
facts": []
summary_paragraphs": []
sources": []
standfirst_ja":
summary_paragraphs": []
sources": []
facts": []
summary_paragraphs": []
sources": []
standfirst_ja":